title: Small molecule mesengenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells.
abstract: The translational potential of mesenchymal stem/stromal cells (MSCs) is limited by their rarity in somatic organs, heterogeneity, and need for harvest by invasive procedures. Induced pluripotent stem cells (iPSCs) could be an advantageous source of MSCs, but attempts to derive MSCs from pluripotent cells have required cumbersome or untranslatable techniques, such as coculture, physical manipulation, sorting, or viral transduction. We devised a single-step method to direct mesengenic differentiation of human embryonic stem cells (ESCs) and iPSCs using a small molecule inhibitor. First, epithelial-like monolayer cells were generated by culturing ESCs/iPSCs in serum-free medium containing the transforming growth factor-β pathway inhibitor SB431542. After 10 days, iPSCs showed upregulation of mesodermal genes (MSX2, NCAM, HOXA2) and downregulation of pluripotency genes (OCT4, LEFTY1/2). Differentiation was then completed by transferring cells into conventional MSC medium. The resultant development of MSC-like morphology was associated with increased expression of genes, reflecting epithelial-to-mesenchymal transition. Both ESC- and iPSC-derived MSCs exhibited a typical MSC immunophenotype, expressed high levels of vimentin and N-cadherin, and lacked expression of pluripotency markers at the protein level. Robust osteogenic and chondrogenic differentiation was induced in vitro in ES-MSCs and iPS-MSCs, whereas adipogenic differentiation was limited, as reported for primitive fetal MSCs and ES-MSCs derived by other methods. We conclude that treatment with SB431542 in two-dimensional cultures followed by culture-induced epithelial-to-mesenchymal transition leads to rapid and uniform MSC conversion of human pluripotent cells without the need for embryoid body formation or feeder cell coculture, providing a robust, clinically applicable, and efficient system for generating MSCs from human iPSCs.
authors.affiliation: The University of Queensland, UQ Centre for Clinical Research, Brisbane, Australia.
authors.forename: Yen Shun
authors.initials: YS
authors.lastname: Chen
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Pelekanos
authors.forename: Rebecca L
authors.initials: RL
authors.lastname: Ellis
authors.forename: Rachel
authors.initials: R
authors.lastname: Horne
authors.forename: Ernst J
authors.initials: EJ
authors.lastname: Wolvetang
authors.forename: Nicholas M
authors.initials: NM
authors.lastname: Fisk
mesh_terms: D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism; D001549:Benzamides / Q000494:pharmacology; D015415:Biomarkers / Q000378:metabolism; D015820:Cadherins / Q000235:genetics / Q000378:metabolism; D018929:Cell Culture Techniques / Q000379:methods*; D002454:Cell Differentiation; D049109:Cell Proliferation; D048430:Cell Shape; D002478:Cells, Cultured; D016895:Culture Media, Serum-Free; D004149:Dioxoles / Q000494:pharmacology; D053595:Embryonic Stem Cells / Q000166:cytology / Q000378:metabolism; D058750:Epithelial-Mesenchymal Transition; D005786:Gene Expression Regulation; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D057026:Induced Pluripotent Stem Cells / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000378:metabolism; D008648:Mesoderm / Q000166:cytology / Q000378:metabolism; D050814:Octamer Transcription Factor-3 / Q000235:genetics / Q000378:metabolism; D044968:Regenerative Medicine / Q000379:methods; D013997:Time Factors; D014746:Vimentin / Q000235:genetics / Q000378:metabolism
chemical_list: C459179:4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide; D015703:Antigens, CD; D001549:Benzamides; D015415:Biomarkers; C050361:CDH2 protein, human; D015820:Cadherins; D016895:Culture Media, Serum-Free; D004149:Dioxoles; D050814:Octamer Transcription Factor-3; C494173:POU5F1 protein, human; D014746:Vimentin